News & Research
New studies, trials, regulatory changes and news about the compounds on Amino WRX. Items are collected automatically once a day and summarised by AI; they are not reviewed by an editor before they appear here. Read the original source before relying on anything.
Last updated 2026-10-17.
- The Lancet: ICYMI on orforglipron ACHIEVE-4
The Lancet
The Lancet highlighted phase 3 ACHIEVE-4 data in which orforglipron was non-inferior to insulin glargine for a four-component major cardiovascular outcome. The people studied had type 2 diabetes and higher cardiovascular risk, and the post was a reminder rather than a first release.
- Retatrutide and Survodutide Make Inroads Into Weight Loss for Diabetic Patients
TCTMD
In adults with obesity and type 2 diabetes, once-weekly survodutide cut weight by 13.1% at 6.0 mg and 10.4% at 3.6 mg after 76 weeks, versus 3.1% on placebo, in SYNCHRONIZE-2 published in NEJM. The same report says retatrutide cut weight by about 19% at the 9 mg and 12 mg doses after 80 weeks, versus about 4% on placebo, in TRIUMPH-2 published in The Lancet.
- Zurich doctors report a woman hospitalized after a life coach injected an unverified retatrutide product
Peptide News Digest
Doctors in Zurich reported that a woman was hospitalized with days of vomiting after a life coach gave her four rising doses of an unapproved product said to contain retatrutide. The case is a safety signal about unverified research-chemical injections, not a controlled result for pharmaceutical retatrutide.
- WHO endorses lifestyle changes over GLP-1 drugs in child obesity fight
Reuters
New WHO child-obesity guidance advises against weight-loss drugs under age 10 and allows them at ages 10 to 19 only after supervised lifestyle care has failed. It cites limited GLP-1 evidence on safety and long-term effectiveness, while noting Wegovy and Saxenda are already approved for some adolescents.
- News2026-10-07Trump administration paving way for temporary sale of some unapproved peptides
The Washington Post
Officials are discussing temporary enforcement discretion that could let compounding pharmacies dispense some previously restricted, unapproved peptides before formal rulemaking. No policy has been announced, timing is unclear, and the peptides have not been named.
- Orforglipron Shows CV Safety vs Insulin Glargine in ACHIEVE-4
Pharmacy Times
Phase 3 ACHIEVE-4, published in The Lancet, found once-daily orforglipron was noninferior to insulin glargine for major cardiovascular events in 2,749 high-risk adults with type 2 diabetes. People taking orforglipron lost more weight, reduced A1C more, and had less hypoglycemia, but had more gastrointestinal side effects.
- Semaglutide Normalized Liver Fat in Most Adults With Obesity
Pharmacy Times
A post hoc MRI subgroup from STEP UP, presented at EASD 2026, found that pooled semaglutide 7.2 mg and 2.4 mg lowered mean liver fat from 8.8% to 3.1% at 72 weeks in adults with obesity. No placebo comparison was reported for that endpoint, so the drug-specific effect is uncertain.
- Orforglipron Shows Greater A1C, Weight Reduction Than Oral Semaglutide
Drug Topics
An indirect comparison estimated that orforglipron 17.2 mg reduced weight by about 1.5 percentage points and A1C by about 0.3 percentage points more than oral semaglutide 25 mg at 52 weeks. It was not a head-to-head trial, so the difference is less certain than a direct comparison.
- The Week Progress Got More Specific
Vastkind
A briefing on the TRIUMPH-2 diabetes trial of retatrutide (GLP3-R) separates an 18.8% treatment-regimen weight-loss figure from a 20.8% efficacy estimate. It also notes a planned United States filing in early 2027, which is a regulatory step and not an approval.
- CagriSema Curbs 'Food Noise,' Organ Fat in Patients With Obesity, T2D Respectively
Pharmacy Times
EASD abstracts reported that cagrilintide plus semaglutide changed brain responses to high-calorie food cues and reduced liver and pancreas fat. An FDA weight-management decision is expected in the fourth quarter of 2026, so the pages should record that timeline without treating conference abstracts as a full regrade.
- New Easier-to-Use GLP-1 Pill Safe for the Heart, Study Says
MedPage Today
ACHIEVE-4 found orforglipron noninferior to insulin glargine for MACE-4, 4.2% versus 5.0%, hazard ratio 0.84, but it was not powered to prove a cardiovascular benefit. The orforglipron page should call this a heart-safety comparison, not evidence that the pill prevents cardiovascular events.
- Ozempic Rival Delivers 25% Weight Loss at Highest Dose in Phase 3 Trial
ScienceAlert
The NEJM TRIUMPH-1 trial reported about 25% weight loss at 80 weeks on retatrutide 12 mg in obesity without diabetes, and nearly 30% in a smaller two-year extension. That non-diabetes result should be stated separately from the type 2 diabetes trial on the GLP3-R page.
- Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
Pharmacy Times
Phase 3 TRIUMPH-2, published in The Lancet, found retatrutide, sold in research channels as GLP3-R, cut weight by up to 18.8% at 80 weeks in type 2 diabetes, with more hypotension and dysesthesia. Lilly is aiming at an FDA filing in early 2027, which is not an approval.
- Orforglipron Noninferior to Insulin Glargine for Cardiovascular Outcomes in T2D
Medscape
The same ACHIEVE-4 readout found better A1c and weight than insulin glargine, while gastrointestinal events drove discontinuation in 15.4% versus 5.4%. Those tolerability figures belong in the orforglipron safety section beside the cardiovascular result.
- Retatrutide trial: Triple action jab can cause weight loss of up to 25%, results suggest.
BMJ
BMJ reported phase 3 retatrutide results suggesting weight loss of up to 25%. Use it as a journal pointer for GLP3-R, and prefer the primary trial paper for dose, duration, and population.
- Orforglipron Edges Oral Semaglutide 25 mg in T2D, Indirect Comparison Finds
Pharmacy Times
A Lilly-funded cross-trial model, not a head-to-head study, linked orforglipron 17.2 mg to about 1.5% more weight loss and 0.3% more A1C reduction than oral semaglutide 25 mg. The site should not upgrade comparative claims from this indirect sponsored analysis.